本次获得FDA的FTD，将有助于加快依帕戈替尼在全球范围内的临床开发与监管审评进程。和誉医药将 持续推进该项目的国际化临床布局，致力于为全球HCC患者提供更加精准有效的创新治疗方案。 和誉-B(02256)发布公告，美国食品药品监督管理局(FDA)已授予和誉医药自主研发的高选择性小分子 FGFR4抑制剂依帕戈替尼(Irpagratinib/ABSK-011)快速通道资格认定(FTD)，用于治疗既往接受过免疫检 查点抑制剂(ICIs)和多靶点激酶抑制剂(mTKIs)治疗，且存在FGF19过表达的肝细胞癌(HCC)患者。 ...

长江商报消息 ●长江商报记者 沈右荣 信达生物再度与礼来公司签合作协议，共同推进全球创新药研发进程。 牵手全球制药巨头，信达生物（01801.HK）签下了一笔天价出海订单。 2月8日晚，信达生物公告，公司与礼来公司达成战略合作，携手推进肿瘤及免疫领域创新药物的全球研发。 根据合作协定，信达生物将主导相关项目从药物发现至中国临床概念验证（二期临床试验完成）的研发工作，礼 来获得相关项目在大中华区以外的全球独家开发与商业化许可。 协议约定，信达生物将获得88.5亿美元（约合人民币613亿元）的总付款，包括首付款3.5亿美元、里程碑付款85亿 美元。 成立于2011年的信达生物，2015年就开始与礼来公司开展合作，算上上述协议，二者累计签署了七份合作协议。 高强度研发投入之下，信达生物曾长期亏损，但在2025年，公司经营业绩出现质的变化。2025年上半年，公司实 现的归母净利润为8.34亿元，首次真正实现了盈利。 为了创新药研发，2021年至2024年，信达生物的研发投入合计超过百亿元。 二级市场上，信达生物获得了投资者认可。近一年，公司股价翻倍上涨，目前市值超过千亿元。 第七次与礼来签合作协议 根据最新公告，信达 ...

Core Viewpoint - Jiuyuan Gene's self-developed innovative drug JY54 injection has received formal acceptance for clinical trial application by the National Medical Products Administration, marking a significant step in the company's focus on metabolic disease treatment [1][2] Group 1: Product Development - JY54 injection is a long-acting glucagon-like peptide-1 (GLP-1) analog aimed at weight management for overweight or obese individuals, with the first phase of clinical research planned to evaluate its safety, tolerability, pharmacokinetics, and pharmacodynamics [1] - The drug's molecular design has undergone systematic optimization to enhance drug stability and pharmacokinetic characteristics, potentially supporting long-acting administration [1] Group 2: Strategic Positioning - Jiuyuan Gene is expanding into high-tech metabolic treatment areas, reflecting its ongoing investment in innovative drug development [1] - The company has established a clear gradient layout in its product pipeline, combining mature target products with innovative mechanisms to meet current market demands and explore future weight loss treatment directions [2]

Core Viewpoint - The collaboration between Innovent Biologics and Eli Lilly marks the seventh partnership aimed at advancing innovative drugs in oncology and immunology, with Innovent leading the development and retaining rights in Greater China while Eli Lilly secures global rights outside this region [1][2]. Group 1: Financial Aspects - Innovent will receive an upfront payment of $350 million and potential milestone payments totaling up to $8.5 billion [1]. - Following the announcement, Innovent's stock price surged by 7.42%, closing at HKD 85.40 per share, with a market capitalization of HKD 148.2 billion [2]. Group 2: Strategic Importance - The collaboration is characterized as a pure incremental partnership, focusing on new targets and molecules outside Innovent's existing clinical pipeline [2]. - Innovent's management highlighted the recognition of its R&D capabilities globally and the long-standing relationship with Eli Lilly as key factors for this partnership [2]. Group 3: Historical Context - Previous collaborations between Innovent and Eli Lilly include the development of the PD-1 inhibitor, which became a cornerstone product for Innovent after its launch in 2018 [3]. - Innovent has also introduced the GLP-1 dual receptor agonist from Eli Lilly, which is set to launch in 2025, marking a significant addition to its product portfolio [3]. Group 4: Market Position and Future Plans - Innovent is seen as a leading player in the domestic innovative drug sector, having capitalized on significant targets like PD-1 and GLP-1, which are closely associated with Eli Lilly [2][3]. - The company aims to enter a new phase of dual-driven product lines and internationalization by 2025, with plans to establish a global R&D and commercialization platform [8][9]. - Innovent's goal includes having five pipelines enter global multi-center Phase III clinical trials by 2030, with a revenue target of CNY 20 billion by 2027 [9].

证券日报网讯 2月9日，九芝堂在互动平台回答投资者提问时表示，公司主要开展创新药抗凝一类新药 YB209项目、创新型环脂肽类抗生素 YB211项目的研发以及干细胞项目的研发。根据2025年半年度报告 披露，公司研发中心YB209项目完成免疫原性研究的方法开发和验证，完成I期临床收尾、关闭实验中 心；YB211项目完成临床样品制备、2段生殖毒性试验、PK-PD启动，完成临床I期试验并全面启动临床 II期试验，受试者入组等工作。根据公司2025年半年度报告披露：九芝堂美科的缺血耐受人同种异体骨 髓间充质干细胞治疗缺血性脑卒中的临床试验已完成IIa期45例全部受试者入组；人骨髓间充质干细胞 注射液治疗自身免疫性肺泡蛋白沉积症的临床试验已完成10例全部受试者的入组。根据公司2025年8月 27日发布的《关于控股子公司研发新药启动临床试验的公告》披露：九芝堂美科的人骨髓间充质干细胞 注射液治疗孤独症的临床试验已于2025年8月26日召开启动会。 （文章来源：证券日报） ...

Group 1 - The core viewpoint of the article highlights that the company, ShenZhou Cell, plans to invest approximately 83 million to 87 million yuan in research and development (R&D) by 2025 [2] - The company is currently in a growth phase, and maintaining high R&D investment is essential for its future development, which is a common characteristic among innovative drug development companies [2] - As multiple projects progress into mid-to-late clinical research stages, the company's R&D expenditures are expected to remain elevated [2]

Core Viewpoint - Jiuyuan Gene (02566) has received formal acceptance from the National Medical Products Administration (NMPA) for the clinical trial application of its self-developed innovative drug JY54 injection, aimed at weight management in obese or overweight populations [1] Group 1: Drug Development - JY54 injection is a long-acting glucagon-like peptide-1 (GLP-1) analog developed by the company [1] - The drug mimics the action of natural glucagon-like peptide-1, binding to GLP-1 receptors to exert multiple biological effects, including inhibition of glucagon secretion, delayed gastric emptying, and appetite reduction [1] - Preclinical trial data indicates that JY54 injection has shown excellent performance across various pharmacodynamic and safety studies [1] Group 2: Clinical Research - The company plans to conduct Phase I clinical research to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of JY54 injection in subjects [1] - JY54 injection has demonstrated significant drug synergy potential in studies involving combination with existing obesity treatment medications [1] Group 3: Market Potential - Based on its molecular design characteristics and mechanism of action, JY54 injection is expected to support long-acting dosing regimens and exhibit differentiated clinical application potential in the field of weight management [1]

（股 份 代 號：2566） 自願公告 JY54注射液 IND申請獲CDE正式受理 本公告乃由杭州九源基因生物醫藥股份有限公司（「本公司」，連 同 其 附 屬 公 司， 統 稱「本集團」）自 願 作 出，以 告 知 本 集 團 股 東（「股 東」）及潛在投資者有關本集團 之 最 新 業 務 發 展。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. 杭州九源基因生物醫藥股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） 本公司董事（「董 事」）會（「董事會」）欣然宣佈，公司自主開發的化學1類創新藥JY54 注射液新藥臨床試驗（「IND」）申 請，已 獲 國 家 藥 品 監 督 管 理 局（「NMPA」）藥品審 評中心（「CDE」）正 式 受 理。本 公 ...

Core Viewpoint - Baili Tianheng is facing dual pressures of declining performance and stock price due to the shrinkage of its traditional business and the high costs associated with innovative drug development [3][23][25]. Group 1: Performance Fluctuations - Baili Tianheng's 2025 performance forecast indicates an expected revenue of approximately 2.5 billion yuan, a year-on-year decrease of about 57.06%, and a net profit loss of approximately 1.1 billion yuan, a decrease of about 129.67% [5][24]. - In contrast, the company reported a profit of 3.7 billion yuan in 2024, which significantly contributed to its previous financial success [5][24]. - The company's stock price has also seen a significant decline following the poor performance forecast, reflecting market concerns [25][39]. Group 2: Business Transition - The company has historically relied on chemical generic drugs and traditional Chinese medicine, but these segments are now experiencing a decline in revenue and profit margins [8][28]. - From 2022 to 2024, the revenue from chemical drug formulations decreased from 535 million yuan to 322 million yuan, with profit margins dropping from 74.92% to 52.75% [8][28]. - The innovative drug pipeline, while promising, has not yet generated significant revenue, leading to a reliance on licensing income, which was notably high at 5.332 billion yuan in 2024 [9][29]. Group 3: Financial Pressure and Funding Gaps - The company reported a net cash flow from operating activities of -1.892 billion yuan in the first three quarters of 2025, a stark contrast to the 4.059 billion yuan generated in 2024 [13][34]. - As of the end of Q3 2025, accounts receivable rose to 1.867 billion yuan, significantly higher than the 119 million yuan at the end of 2024, indicating increasing financial strain [13][34]. - Baili Tianheng anticipates a total funding gap of approximately 4.819 billion yuan from 2025 to 2027, necessitating external financing to support its operations and innovative drug development [14][36]. Group 4: Shareholder Actions and Market Confidence - A significant shareholder, OAP III (HK) Limited, announced plans to reduce its stake by up to 1% due to personal financial needs, which may impact market confidence [39]. - The stock has experienced a cumulative decline of 31% from its peak in September 2025 to February 2026, reflecting ongoing market skepticism regarding the company's future prospects [39].

Group 1 - China Biologic Products (01177) saw a stock increase of over 3%, reaching HKD 6.68 with a trading volume of HKD 149 million [1] - On February 9, China Biologic announced that its wholly-owned subsidiary, Lixin Pharmaceutical Technology (Shanghai) Co., Ltd., has initiated a Phase III registration clinical trial for its innovative drug, LM-302, targeting CLDN18.2 positive advanced gastric and gastroesophageal junction adenocarcinoma [1] - LM-302 is the first CLDN18.2 ADC drug globally to complete patient enrollment in a Phase III clinical trial [1] Group 2 - At the 2025 American Society of Clinical Oncology (ASCO) annual meeting, Lixin Pharmaceutical presented new research data showing an objective response rate (ORR) of 65.9% and a disease control rate (DCR) of 85.4% in 41 evaluable patients treated with LM-302 combined with Toripalimab for gastric cancer [2] - In patients with CLDN18.2 expression ≥25%, the ORR reached 71.9% and the DCR was 96.9% [2] - The study indicated significant anti-tumor activity and manageable safety profiles for the LM-302 combination therapy in CLDN18.2 positive patients [2]